Dopaminergika-induziertes Pathologisches Glücksspiel

Zusammenfassung

Störungen der Impulskontrolle und pathologisches Spielen sind Erscheinungen, welche bei einer dopaminergen Therapie bei Patienten mit Morbus Parkinson als mögliche Nebenwirkungen bekannt sind. Wir berichten über 2 Fälle von Dopaminergika-induziertem pathologischen Glücksspiel bei nicht an Morbus Parkinson erkrankten Patienten. Der erste Patient war ein 46-jähriger Mann, welcher im Rahmen einer Behandlung eines Restless-Legs-Syndroms mit Ropinirol größere Geldmengen über ein internetbasiertes Pokerspiel verloren hatte. Bei einem weiteren, ebenfalls 46-jährigen Patienten war Cabergolin zur Therapie eines Prolaktinoms verordnet worden, worunter es ebenfalls zur Ausbildung einer Spielsucht gekommen war. Die beschriebenen Fälle zeigen pathologisches Glücksspiel als mögliche Folge einer Therapie mit Dopaminagonisten und stützen die zunehmende Evidenz für das Auftreten pathologischen Spielens als unerwünschte Arzneimittelwirkung dopaminerger Therapien auch bei Patienten, die nicht an Morbus Parkinson erkrankt sind.

Abstract

Problems with impulse control and pathological gambling are known as possible side effects of dopaminergic therapy in patients with Parkinson’s disease. We report 2 cases of pathological gambling induced by dopamine agonists in patients without Parkinson’s disease. The first patient, a 46-year-old man, was treated with ropinirole for restless legs syndrome and had lost huge amounts of money in the context of internet-based poker game. Another 46-year-old male patient developed pathological gambling under treatment with cabergoline administered for prolactinoma. The two cases implicate pathological gambling as a possible consequence of dopaminergic treatment and support the increasing evidence regarding pathological gambling as an adverse drug reaction of dopaminergic treatment, also in patients who do not suffer from Parkinson’s disease.

Schlüsselwörter

Prolaktinom - Cabergolin - Ropinirol - Impulskontrollstörung

Keywords

prolactinoma - cabergoline - ropinirole - impulse control disorder

Literatur

• 1 Everitt B, Robbins T. Neural systems of reinforcement for drug addiction: From actions to habits to compulsion.  Nat Neurosci. 2005;  8 1481-1489
• 2 Dalley J, Fryer T, Brichard L et al. Nucleus accumbens D 2 / 3 receptors predict trait impulsivity and cocaine reinforcement.  Science. 2007;  315 1267-1270
• 3 Cools R. Role of dopamine in the motivational and cognitive control of behavior.  Neuroscientist. 2008;  14 381-395
• 4 Bergh C, Eklund T, Sodersten P et al. Altered dopamine function in pathological gambling.  Psycholog Med. 1997;  27 473-475
• 5 Cooper J. ICD-10 Classification of Mental and Behavioural Disorders with Glossary and Diagnostic Criteria for Research ICD-10:DCR-10. Edinburgh, London, Melbourne, New York, Tokyo; 1994
• 6 Dodd M, Klos K, Bower J et al. Pathological gambling caused by drugs used to treat Parkinson disease.  Arch Neurolog. 2005;  62 1-5
• 7 Gallagher D, O’Sullivan S, Evans A et al. Pathological gambling in Parkinson’s disease: risk factors and differences from dopamine dysregulation. An analysis of published case series.  Movement Disord. 2007;  22 1757-1763
• 8 Voon V, Thomsen T, Miyasaki J et al. Factors associated with dopaminergic drug-related pathological gambling in Parkisnon disease.  Arch Neurolog. 2007;  64 212-216
• 9 Molina J, Sainz-Artiga M, Fraile A et al. Pathological gambling in Parkinson’s disease: A behavioral manifestation of pharmacologic treatment?.  Movement Disord. 2000;  15 869-872
• 10 Driver-Dunckley E, Noble B, Hentz J et al. Gambling and increased sexual desire with dopaminergic medications in restless legs syndrome.  Clin Neuropharmacol. 2007;  30 249-255
• 11 Tippmann-Peickert M, Park J, Boeve B et al. Pathological gambling in patients with restless legs syndrome treated with dopaminergic agonists.  Neurology. 2007;  68 301-303
• 12 Kolla B, Mansukhani M, Barraza R et al. Impact of dopamine agonists on compulsive behaviors: a case series of pramipexole-induced pathological gambling.  Psychosomatics. 2010;  51 271-273
• 13 McElroy S, Philips K, Keck P. Obsessive compulsive spectrum disorder.  J Clin Psychiatr. 1994;  55 (Suppl 19) 33-51
• 14 McElroy S, Hudson J, Philips K et al. Clinical and theoretical implications of a possible link between obsessive-compulsive and impulse control disorders.  Depression. 1993;  1 121-132
• 15 Petry N, Stinson F, Grant B. Comorbidity of DSM IV pathological gambling and other psychiatric disorders: results from the National Epidemiologic Survey on Alcohol and related conditions.  J Clin Psychiatr. 2005;  66 564-574
• 16 Petry N. Gambling and substance use disorder: current status and future directions.  Am J Addict. 2007;  16 1-9
• 17 Holden C. ‘Behavioral’ addictions: do they exist?.  Science. 2001;  294 980-982
• 18 Grant J, Brewer A, Potenza M. The neurobiology of substance and behavioural addictions.  CNS Spectr. 2006;  11 924-930
• 19 Potenza M. Should addictive disorders include non-substance-related conditions?.  Addiction. 2006;  101 (Suppl 1) 142-151
• 20 Bühringer G, Kraus L, Sonntag D et al. Pathologisches Glücksspiel in Deutschland: Spiel- und Bevölkerungsrisiken.  Sucht. 2007;  53 296-308
• 21 BZgA BfgA .Glücksspielverhalten und problematisches Glücksspielen in Deutschland 2007. Ergebnisse einer Repräsentativbefragung. 2008
• 22 Buth S, Stöver H. Glücksspielteilnahme und Glücksspielprobleme in Deutschland: Ergebnisse einer bundesweiten Repräsentativbefragung.  Suchttherapie. 2008;  9 3-11
• 23 Evans A, Strafella A, Weintraub D et al. Impulsive and compulsive behaviors in Parkinson’s disease.  Mov Disord. 2009;  24 1561-1570
• 24 Kim S, Grant J. Personality dimensions in pathological gambling disorder and obsessive-compulsive disorder.  Psychiatry Research. 2001;  104 205-212
• 25 Nordin C, Nylander P O. Temperament and character in pathological gambling.  J Gambl Stud. 2007;  23 113-120
• 26 Breen R, Zuckermann M. Chasing in gambling behavior: personality and cognitive determinants.  J Personality Individual Differences. 1999;  27 1097-1111
• 27 Fiorillo C, Tobler P, Schultz W. Discrete coding of reward probability and uncertainty by dopamine neurons.  Science. 2003;  299 1898-1902
• 28 Evans A, Pavese N, Lawrence A et al. Compulsive drug use linked to sensitized ventral striatal dopamine transmission.  Ann Neurol. 2006;  59 852-858
• 29 Reuter J, Raedler T, Rose M et al. Pathological gambling is linked to reduced activation of the mesolimbic reward system.  Nat Neurosci. 2005;  8 147-148
• 30 Knutson B, Gibbs S. Linking nucleus accumbens dopamine and blood oxygenation.  Psychopharamcol. 2007;  191 813-822
• 31 Potenza M, Leung H C, Blumberg H et al. An fMRI Stroop Tasl Study of Ventromedial Prefrontal Cortical Function in Pathological Gamblers.  Am J Psychiatry. 2003;  160 1990-1994
• 32 Weintraub D, Siderow A, Potenza M et al. Association of dopamine agonist use with impulse control disorders in Parkinson disease.  Arch Neurolog. 2006;  63 969-973
• 33 Johnson P, Madden G, Brewer A et al. Effects of acute pramipexole on preference for gambling-like schedules of reinforcements in rats.  Psychopharmacol. 2011;  213 11-18
• 34 Madden G, Johnson P, Brewer A et al. Effects of pramipexole on impulsive choice in male wistar rats.  Exp Clin Psychopharmacology. 2010;  18 267-276
• 35 Riba J, Kraemer U, Heldmann M et al. Dopamine agonist increase risk taking but blunts reward-related brain activity.  Plos One. 2008;  ;e2479. DOI: 10.1371 /journal.pone.0002479
• 36 Augustijn P, Parra J, Wouters C et al. Ring chromosome 20 epilepsy syndrome in children: electroclinical features.  Neurology. 2001;  57 1108-1111
• 37 Edwards I, Aronson J. Adverse drug reactions: definitions, diagnosis, and management.  Lancet. 2000;  356 1255-1259
• 38 Naranjo C, Busto U, Sellers E et al. A method for estimating the probability of adverse drug reactions.  Clin Pharmacol Ther. 1981;  30 239-245
• 39 Davie M. Pathological gambling associated with cabergoline.  J Neuropsychiatry Clin Neurosci. 2007;  19 473-474
• 40 Falhammar H, Yarker J. Pathological gambling and hypersexuality in cabergoline-treated prolactinoma.  MJA. 2009;  190 97